Stifel initiated coverage on DarioHealth with a new price target
$DRIO
Medical/Dental Instruments
Health Care
Stifel initiated coverage of DarioHealth with a rating of Buy and set a new price target of $30.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/29/2025 | $2.00 → $1.00 | Buy → Hold | TD Cowen |
| 5/13/2022 | $8.75 | Neutral → Buy | Alliance Global Partners |
| 1/26/2022 | $28.00 → $25.00 | Buy | Aegis Capital |
| 8/19/2021 | $35.00 → $28.00 | Buy | Aegis Capital |
4 - DarioHealth Corp. (0001533998) (Issuer)
4 - DarioHealth Corp. (0001533998) (Issuer)
4 - DarioHealth Corp. (0001533998) (Issuer)
4 - DarioHealth Corp. (0001533998) (Issuer)
4 - DarioHealth Corp. (0001533998) (Issuer)
4 - DarioHealth Corp. (0001533998) (Issuer)
Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced the appointments of Avril McKean Dieser, MA, JD and Olivier R. Jarry, MS, MBA as independent members of the Company's Board of Directors. Collectively, Ms. McKean Dieser and Mr. Jarry bring over 50 years of biopharmaceutical executive decision-making experience to the Company, with a specific focus in commercializing biologic products. "OS Therapies is thrilled to welcome Ms. McKean Dieser and Mr. Jarry to our Board of Directors," sa
After two decades of successfully scaling multiple healthcare companies, Steven Nelson joins DarioHealth as Chief Commercial Officer to accelerate revenue growth across the health plans, employers and pharma channels NEW YORK, June 5, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario", "DarioHealth" or the "Company"), a leader in the global digital health market, announced today a strategic reorganization designed to streamline leadership and focus the organization on accelerating its commercialization efforts. This move reflects the Company's commitment to bringing its innovative solutions to the market faster, maximizing customer impact, and driving the organization to profitabi
Dario also appoints digital veteran, Arnaud Robert, to the role of Strategic Advisor to the Chief Executive Officer The appointments strengthen Dario's ability to scale its digital therapeutics platform to meet growing market demand NEW YORK, April 4, 2023 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company" or "Dario"), a leader in the global digital therapeutics (DTx) market, announced today that digital health veteran, Eitan Shay, is joining the Company in the newly created position of Chief Product Officer. Mr. Shay previously held product leadership roles at digital health companies Livongo and Teladoc Health as well as senior leadership roles at Meta Platforms. Dario also
Significant participation from existing shareholders and accredited healthcare investors, which the company believes underscores confidence in its strategyFinancing supports execution of long-term growth initiatives focused on high-margin, scalable recurring revenues across B2B (Business-to-Business) and pharma channelsNEW YORK, Jan. 21, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a prominent leader in the global digital health industry, announced today the successful closing of a $25.6 million private placement of convertible preferred stock, priced in accordance with Nasdaq market rules. The majority of the funds were secured from existing shareholders,
Demonstrated strong improvements in financial performance and business momentum.Q3 revenue of $7.42 million increased 18.7% over Q2 2024 and 111% compared to Q3 2023, driven by expansion of B2B2C revenues.Q3 operating loss decreased sequentially by 25.7% to $12 million on a GAAP basis and by 33.3% to $7.1 million on a non-GAAP basis over Q2 2024.Executed synergies from the Dario-Twill merger, expected to reduce operating expenses by approximately 38% by Q1 2025 (compared to Q1 2024) and contributing to an expected 49% reduction in operating losses by Q1 2025 and 59% in non-GAAP operating losses.Significant wins include: 10 B2B2C clients, including a national Medicare advantage health plan, a
Company to host conference call and webcast at 8:30am ET NEW YORK, Oct. 23, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a global leader in digital health, announced today that it will release its financial results for the 3rd quarter ended September 30th, 2024 and will host a conference call and webcast at 8:30 am Eastern Time, on Thursday, November 7th, 2024, before the market opens. Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call. Conference Call Details Date: Thursday, November 7th, 8:30am ET Dial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international) Call me™: https://emportal
Significant participation from existing shareholders and accredited healthcare investors, which the company believes underscores confidence in its strategyFinancing supports execution of long-term growth initiatives focused on high-margin, scalable recurring revenues across B2B (Business-to-Business) and pharma channelsNEW YORK, Jan. 21, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a prominent leader in the global digital health industry, announced today the successful closing of a $25.6 million private placement of convertible preferred stock, priced in accordance with Nasdaq market rules. The majority of the funds were secured from existing shareholders,
Market News Alerts Updates that DarioHealth Corp. (NASDAQ:DRIO) is taking another bold step into the rapidly growing weight-loss market, now projected to exceed $100 billion annually by 2030. The company's latest move expands its GLP-1 offering with prescribing capabilities, positioning Dario to capture a larger share of this lucrative space as demand for medical weight-loss solutions skyrockets across employers and consumers. Following the announcement, Dario's shares surged nearly 14%, reflecting investor excitement over this significant growth opportunity. The market for GLP-1 medications, driven by blockbuster drugs like Novo Nordisk's Ozempic and Wegovy, is transforming how obesity a
New collaboration enhances Dario's comprehensive GLP-1 offering with virtual physician management to meet growing demand from employers covering weight-loss medications, opening new revenue streams in direct-to-consumer and pharma channels NEW YORK, Jan. 14, 2025 /PRNewswire/ -- January 14, 2025 -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced a collaboration with MediOrbis, a multi-specialty digital health provider, to add prescribing capabilities to Dario's GLP-1 behavior change solution for a comprehensive medical weight loss program. This strategic addition creates a fully integrated solution for employers coveri
8-K - DarioHealth Corp. (0001533998) (Filer)
D - DarioHealth Corp. (0001533998) (Filer)
D - DarioHealth Corp. (0001533998) (Filer)
TD Cowen downgraded DarioHealth from Buy to Hold and set a new price target of $1.00 from $2.00 previously
Alliance Global Partners upgraded DarioHealth from Neutral to Buy and set a new price target of $8.75
Aegis Capital reiterated coverage of DarioHealth with a rating of Buy and set a new price target of $25.00 from $28.00 previously
SC 13G - DarioHealth Corp. (0001533998) (Subject)
SC 13G - DarioHealth Corp. (0001533998) (Subject)
SC 13G/A - DarioHealth Corp. (0001533998) (Subject)